Nuvectis Pharma Investor Presentation Deck
Potential Combination Strategies
YES1 (in NSCLC) and SRC (in mCRPC) are implicated in development of resistance to osimerinib (Tagrisso) and
enzalutamide (Xtandi)
NXP900 in combination with osimertinib overcomes resistance in vitro
Proliferation
(% of DMSO control)
100
80-
60-
40-
20-
Osimertinib resistance in PC-9
0.01
0.1
1
Osimertinib (UM)
PC-9
PC-9 OR1
PC-9 OR3
THIT
NuvectisPharma, Inc.
Proliferation
(% of DMSO control)
10
Osimertinib re-sensitisation in PC-9
100
80-
60-
40-
20-
0.1
1
ECF-506 (UM)
Published in Nature Communications by the AstraZeneca R&D Group, April 2022
0
- PC-9
-PC-9 OR1 (Osi 160 nM)
-PC-9 OR3 (Osi 160 nM)
0.01
F
10
NXP900 in combination with enzalutamide overcomes
resistance in vivo
Day -7
D 14
D 21
Enz -/eCF506
H
0
Enz
NSCLC = non=small cell lung cancer, mCRPC = metastatic castration resistant prostate cancer, eCF506 = NXP900
14
Enz
eCF506
21BLI
1e04
5e05-
Relative BLI signal
Normalised to Day 14
1500
1000
500
Enz
Enz+eCF506
Published in JEM by UoE and MSKCC, February 2023
***
14
18
21
Days after treatment
20View entire presentation